UNSPSC 51123108: Encainide hydrochloride

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H28N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CH7J36N9S, chemically known as benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, monohydrochloride, (+-)- but more generally known as encainide hydrochloride, which bears US NIH Compound Identifier 48040.

UNSPSC 51123108 Encainide hydrochloride, a Commodity code, represents a specific cardiac antiarrhythmic pharmaceutical that state and local governments procure primarily through emergency medical services and public health programs. Recent solicitation activity shows state and local buyers sourcing this and related advanced life support medications for fire rescue operations, pharmacy benefit programs, and cooperative purchasing agreements spanning multiple jurisdictions. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission exemplify the issuing-body mix — municipalities managing emergency services procurement and state health agencies coordinating pharmacy benefit strategy — with multistate cooperative purchasing alliances such as MMCAP aggregating demand across participating state and local facilities to achieve volume pricing and supply consistency.

Activity concentrates in Florida, Texas, and Minnesota, with secondary reach into Oregon through multistate cooperative arrangements. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications, including encainide-class compounds alongside labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, due April 8, 2026, with a contract value estimated at $40,000 and a one-year initial term plus renewal options. The Minnesota Department of Administration's Office of State Procurement released RFP S1070000015802 through MMCAP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendor partnerships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and effective July 1, 2026. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels, indicating early-stage procurement development in that state. Small-business set-asides appear in municipal solicitations; MMCAP procurement emphasizes price competitiveness (75 percent weighting) and cGMP/DSCSA compliance across multistate networks.